COMPASS Pathways plc (NASDAQ:CMPS) Shares Bought by ARK Investment Management LLC

ARK Investment Management LLC raised its holdings in COMPASS Pathways plc (NASDAQ:CMPS) by 7.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,618,871 shares of the company’s stock after purchasing an additional 186,040 shares during the quarter. ARK Investment Management LLC owned 4.23% of COMPASS Pathways worth $22,915,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. TAP Consulting LLC raised its position in COMPASS Pathways by 14.7% in the third quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock valued at $95,000 after purchasing an additional 1,645 shares during the period. RA Capital Management L.P. purchased a new stake in COMPASS Pathways in the third quarter valued at $9,516,000. Laurion Capital Management LP raised its position in COMPASS Pathways by 169.7% in the third quarter. Laurion Capital Management LP now owns 510,907 shares of the company’s stock valued at $3,781,000 after purchasing an additional 321,500 shares during the period. Armistice Capital LLC purchased a new stake in COMPASS Pathways in the third quarter valued at $2,960,000. Finally, Tower Research Capital LLC TRC raised its position in COMPASS Pathways by 229.6% in the third quarter. Tower Research Capital LLC TRC now owns 7,847 shares of the company’s stock valued at $58,000 after purchasing an additional 5,466 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Price Performance

CMPS stock opened at $9.50 on Thursday. The business’s fifty day moving average price is $10.34 and its 200 day moving average price is $8.28. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.14. COMPASS Pathways plc has a 12-month low of $5.01 and a 12-month high of $12.75. The company has a market capitalization of $588.46 million, a PE ratio of -3.97 and a beta of 2.52.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, sell-side analysts anticipate that COMPASS Pathways plc will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

CMPS has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on COMPASS Pathways in a report on Tuesday, December 12th. They issued a “buy” rating and a $16.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of COMPASS Pathways in a report on Friday, March 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $49.00.

Insiders Place Their Bets

In other news, Director Ekaterina Malievskaia sold 19,853 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total transaction of $210,243.27. Following the completion of the transaction, the director now directly owns 4,144,994 shares of the company’s stock, valued at approximately $43,895,486.46. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Ekaterina Malievskaia sold 19,853 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total value of $210,243.27. Following the completion of the sale, the director now directly owns 4,144,994 shares of the company’s stock, valued at approximately $43,895,486.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director George Jay Goldsmith sold 25,750 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $8.35, for a total value of $215,012.50. Following the completion of the sale, the director now directly owns 4,172,404 shares of the company’s stock, valued at $34,839,573.40. The disclosure for this sale can be found here. Insiders have sold a total of 111,175 shares of company stock worth $1,058,199 in the last quarter. 23.99% of the stock is owned by company insiders.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.